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Abstract: The so-called Western diet is rich in saturated fat and sugars and poor in plant-derived
fibers, and it is associated with an increased risk of metabolic and cardiovascular diseases, as well
as chronic (low grade) inflammation. The detrimental effects of poor diet are in part mediated by
gut microbiota, whose composition, functionality and metabolic end products respond to dietary
changes. Recent studies have shown that high intake of sugars increase the relative abundance of
Proteobacteria in the gut, while simultaneously decreasing the abundance of Bacteroidetes, which can
mitigate the effects of endotoxin, as well as reinforce gut barrier function. Thus, a high sugar intake
may stagger the balance of microbiota to have increased pro-inflammatory properties and decreased
the capacity to regulate epithelial integrity and mucosal immunity. Consequently, high dietary sugar
can, through the modulation of microbiota, promote metabolic endotoxemia, systemic (low grade)
inflammation and the development of metabolic dysregulation and thereby, high dietary sugar may
have many-fold deleterious health effects, in addition to providing excess energy.
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The so-called Western diet is characterized by consumption of highly processed food and a
high intake of saturated fat and sugars and a low intake of vegetables, fruits and dietary fiber [1].
The Western dietary pattern is associated with an increased risk of metabolic disorders, obesity and
cardiovascular diseases, and chronic systemic inflammation is considered as one of the key components
involved in the etiopathology of these disorders [1–3]. Metabolic endotoxemia as a result of increased
gut permeability and leakage of bacterial lipopolysaccharide (LPS) from gut lumen into the systemic
circulation has received considerable interest during the past decade, as it is considered to be a major
route for the induction and persistence of inflammation [3].
Concerning the Western diet, both fat and sugars have been studied in mouse models in relation
to gut permeability. High dietary fat per se can increase gut permeability via modifying bile acid
concentrations and inducing deoxycholic acid-mediated barrier dysfunction [4], and the detrimental
effect can be further amplified by fat-induced changes to microbiota composition and functionality [5].
Recently, Do et al. investigated the effects of a high-glucose or -fructose diet on gut microbiota and
intestinal permeability, as well as on blood endotoxin levels, inflammation and fat accumulation
in a mouse model [6]. High dietary sugar was found to drive changes in microbiota composition,
specifically decreasing bacterial diversity and the abundance of Bacteroidetes and increasing the
abundance of Proteobacteria [6]. Concurrently, gut epithelium showed inflammatory changes and
impaired integrity, and the animals developed metabolic endotoxemia and hepatic steatosis, while
remaining normal-weight [6].
The observed microbial changes induced by high dietary sugar, i.e., reduced diversity, increased
abundance of Proteobacteria and decreased abundance of Bacteroidetes [6], share common features
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with microbiota dysbiosis associated with metabolic disorders, inflammatory bowel diseases (IBD) and
other human disorders [1,3,7]. Excess monosaccharides that are not absorbed in the small intestine
can favor organisms that can rapidly utilize simple carbohydrates, such as Proteobacteria, at the
expense of other commensals, which are specialized in degrading complex carbohydrates and generally
have slower growth rates [8]. Thus, high dietary sugar can have deleterious consequences also by
modulating microbiota, in addition to providing excess energy.
Proteobacteria form a minor part of healthy gut microbiota, but if they are increased
disproportionately, unspecific inflammation may ensue [9,10]. Class gamma-Proteobacteria and
family Enterobacteriaceae within the phylum carry lipopolysaccharide (LPS, endotoxin) molecules that
are strong triggers of inflammatory responses [9–11]. In enterocytes, LPS induces release of interleukin
8 (IL-8)—a key chemokine responsible for inducing inflammatory responses, which, in turn, transmute
tight junctions and lead to impairment of epithelial integrity [11,12]. LPS of other Gram-negative
bacteria can differ structurally from that of gamma-Proteobacteria and, therefore, may not have strong
pro-inflammatory properties [11], as in the case of Bacteroides spp. [12].
Bacteroidetes and Firmicutes are the two most abundant bacterial phyla in healthy adult
microbiota. Bacteroides, a predominant genus within Bacteroidetes, is well adapted to the competitive
gut environment and utilization of complex plant- and host-derived polysaccharides [13,14]. The genus
has been associated with numerous health benefits, including the downregulation of inflammatory
responses in the gut, although one should bear in mind that the relationship with the host is always
context-dependent [13,14]. Concerning the counterbalancing effects, in vitro studies have shown that
Bacteroides spp. can reduce IL-8 release from enterocytes in response to enterobacterial LPS i.e., to
attenuate inflammatory responses, as well as to reinforce enterocyte monolayer integrity [12]. Specific
strains of Bacteroides have shown capability to alleviate the LPS-induced inflammation also in vivo
in mice [15]. Thus far, polysaccharide (PSA), sphingolipids and short-chain fatty acids (SCFA) have
been identified as the effector molecules and metabolites mediating the immunomodulatory action of
Bacteroides [14], but the underlying mechanisms are still largely unexplored.
It seems plausible that the balance between Proteobacteria and Bacteroidetes plays a role in the
maintenance of immunological homeostasis and epithelial integrity in the intestinal mucosa. In line
with this, a recent study showed that the level of IL-8 expression in enterocytes correlated positively
with Enterobacteriaceae in the fecal microbiota of IBD patients, who also had a reduced abundance of
Bacteroides spp., Faecalibacterium prausnitzii and Prevotella spp. [16]. On the other hand, both precision
editing of the microbiota to decrease the relative abundance of Enterobacteriaceae [17], as well as oral
supplementation with Bacteroides sp. [18], have been shown to ameliorate inflammation in murine
models of experimental colitis.
High sugar intake seems to stagger the balance of microbiota, by modifying the ratio
of Proteobacteria and Bacteroidetes, to have increased pro-inflammatory properties, decreased
immune-regulatory functions and decreased capacity to regulate epithelial integrity [6]. Do et al.
observed that a high-glucose or -fructose diet resulted, in addition to the aforementioned changes in
gut microbiota, in increased gut inflammation and permeability in mice [6]. More recently, a high
simple sugar diet was found to increase small intestinal permeability in healthy humans [19].
In the mouse model study by Do et al., changes in gut microbiota, intestinal inflammation and
permeability finally led to metabolic endotoxemia, increased fat accumulation and hepatis steatosis [6].
Interestingly, the changes occurred without changes in bodyweight resulting in so-called normal weight
obesity [6], which, in humans, is linked to metabolic dysregulation and higher risk of developing
metabolic syndrome and cardiometabolic dysfunction [20]. Taken together, it can be concluded that a
high dietary sugar can increase the risk of metabolic disorders in normal weight subjects. Considering
the tight connection of microbiota and its very likely mechanistic involvement in the development of
obesity, normal-weight obesity and the associated metabolic complications, modulation of microbiota
as an adjunct therapy, in addition to diet management, could provide an attractive approach to the
management of these conditions and to mitigate the harmful effects dietary sugar.
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